Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Antibiotic Class Is Aim Of Evotec R&D Pact With Nosopharm

Executive Summary

Evotec and Nosopharm plan to develop and then test in humans the first novel antibiotic class for fighting Gram-negative Enterobacteriaceae infections in 40 years

You may also be interested in...



Deal Watch: Genentech Inks New Collaborations With Skyhawk, Convelo

Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.

ConserV Says Its Vaccine R&D Is 'Aimed At The Next Pandemic’

ConserV CEO tells Scrip why the late-stage vaccine developer has entered an mRNA development pact with eTheRNA of Belgium and about the UK biotech’s hopes for finding a universal jab against the entire coronavirus family.

Arena Cannabinoid Pain Compound Misses In Phase IIb IBS Trial

Arena's Phase IIb CAPTIVATE trial assessing investigational olorinab in IBS missed its primary endpoint.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel